Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Che...
October 23 2017 - 7:00AM
Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading
developer of placenta-based cell therapy products, announced today
that the European Patent Office has issued the company a patent
titled, “Methods for Treating Radiation or Chemical Injury” for its
PLX-R18 cell therapy.
Pluristem currently holds several patents
worldwide to cover placental 3D-expanded cells in the treatment of
impaired hematopoietic systems when a bone marrow, cord blood, or
peripheral blood transplant takes place. This important patent
expands Pluristem’s IP assets to include a new set of indications
related to the bone marrow’s inability to produce blood cells, such
as acute radiation syndrome (ARS), autoimmune diseases such as
aplastic anemia, genetic disorders, chemotherapy, radiation
therapy, and side effects from other treatments. Pluristem
currently holds over 115 issued patents and 100 pending patent
applications worldwide.
“PLX-R18 is covered by several patents in key
markets for the treatment of bone marrow failure following a
transplant of hematopoietic stem cells, or for the support of such
a transplant. What makes this a key patent for our IP assets is
that it addresses the treatment of a much broader range of medical
conditions in which bone marrow is damaged and the patient has not
received a transplant,” stated Yaky Yanay, Co-CEO and President of
Pluristem. “PLX-R18 cells have shown the ability to trigger
regeneration of the hematopoietic system, thereby supporting the
recovery and production of white blood cells, red blood cells and
platelets. With its capabilities, we believe that PLX-R18 has
the potential to treat a broad range of hematologic indications,
which together constitute a substantial global market.”
About PLX-R18
PLX-R18 is Pluristem’s second cell therapy
product in development. It is designed to treat bone marrow that is
unable to produce enough blood cells due to a variety of causes,
including acute radiation syndrome (ARS), certain cancers or cancer
treatments, or immune-mediated bone marrow failure. PLX-R18’s first
animal studies to prove their activity in ARS, as reflected in the
new patent, were performed in collaboration with Prof. Gorodetsky
at Hadassah Medical Center. Further preclinical data from trials
conducted by the U.S. National Institutes of Health, Hadassah, the
Charite in Berlin and other prominent research institutions have
shown that PLX-R18 cells secrete a range of specific proteins that
trigger the regeneration of bone marrow hematopoietic cells,
thereby supporting the recovery of blood cell production. Pluristem
is currently enrolling patients in a U.S. Phase I trial of PLX-R18
in incomplete bone marrow recovery following hematopoietic cell
transplantation (HCT) and is preparing for a pivotal trial in
ARS.
About Pluristem
Therapeutics
Pluristem Therapeutics Inc. is a leading
developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its
patented PLX (PLacental eXpanded) cells, and is entering late-stage
trials in several indications. PLX cell products release a range of
therapeutic proteins in response to inflammation, ischemia, muscle
trauma, hematological disorders, and radiation damage. The cells
are grown using the Company's proprietary three-dimensional
expansion technology and can be administered to patients
off-the-shelf, without tissue matching. Pluristem has a strong
intellectual property position; Company-owned and operated,
GMP-certified manufacturing and research facilities; strategic
relationships with major research institutions; and a seasoned
management team.
Safe Harbor Statement
This press release contains express or implied
forward-looking statements within the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. For
example, Pluristem is using forward-looking statements when its
discusses that it believes that PLX-R18 has the potential to treat
a broad range of hematologic indications and when it discusses the
progress of its Phase I trial of PLX-R18 in the U.S. as well as its
pivotal trial in ARS. These forward-looking statements and their
implications are based on the current expectations of the
management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements;
Pluristem may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; Pluristem’s products
may not be approved by regulatory agencies, Pluristem’s technology
may not be validated as it progresses further and its methods may
not be accepted by the scientific community; Pluristem may be
unable to retain or attract key employees whose knowledge is
essential to the development of its products; unforeseen scientific
difficulties may develop with Pluristem’s process; Pluristem’s
products may wind up being more expensive than it anticipates;
results in the laboratory may not translate to equally good results
in real clinical settings; results of preclinical studies may not
correlate with the results of human clinical trials; Pluristem’s
patents may not be sufficient; Pluristem’s products may harm
recipients; changes in legislation may adversely impact Pluristem;
inability to timely develop and introduce new technologies,
products and applications; loss of market share and pressure on
pricing resulting from competition, which could cause the actual
results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
Contact: Karine Kleinhaus, MD,
MPH Divisional VP, North America 1-914-512-4109
karinek@pluristem.com
Efrat Kaduri Head of Investor and Public
Relations 972-74-7108600 efratk@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Sep 2023 to Sep 2024